|
US6759398B2
(en)
|
2000-08-05 |
2004-07-06 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative
|
|
US6777400B2
(en)
|
2000-08-05 |
2004-08-17 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
|
GB0019172D0
(en)
|
2000-08-05 |
2000-09-27 |
Glaxo Group Ltd |
Novel compounds
|
|
US6858596B2
(en)
|
2000-08-05 |
2005-02-22 |
Smithkline Beecham Corporation |
Formulation containing anti-inflammatory androstane derivative
|
|
US6750210B2
(en)
|
2000-08-05 |
2004-06-15 |
Smithkline Beecham Corporation |
Formulation containing novel anti-inflammatory androstane derivative
|
|
PT1305329E
(pt)
|
2000-08-05 |
2007-12-24 |
Glaxo Group Ltd |
Éster s-fluorometílico do ácido 6.alfa.,9.alfa.-difluoro- 17.alfa.-(2-furanilcarboxil)oxi-11.beta.-hidroxi-16.alfa.-metil- 3-oxo-androsta-1,4-dieno-17-carbotióico como um agente antiinflamatório
|
|
US6777399B2
(en)
|
2000-08-05 |
2004-08-17 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
|
US6787532B2
(en)
|
2000-08-05 |
2004-09-07 |
Smithkline Beecham Corporation |
Formulation containing anti-inflammatory androstane derivatives
|
|
US6858593B2
(en)
|
2000-08-05 |
2005-02-22 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
|
GB0103630D0
(en)
|
2001-02-14 |
2001-03-28 |
Glaxo Group Ltd |
Chemical compounds
|
|
UA77656C2
(en)
|
2001-04-07 |
2007-01-15 |
Glaxo Group Ltd |
S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
|
|
MY137522A
(en)
|
2001-04-30 |
2009-02-27 |
Glaxo Group Ltd |
Novel anti-inflammatory androstane derivatives.
|
|
RU2312854C2
(ru)
|
2001-09-14 |
2007-12-20 |
Глаксо Груп Лимитед |
Производные фенэтаноламина для лечения респираторных заболеваний
|
|
US8337816B2
(en)
|
2001-09-17 |
2012-12-25 |
Glaxo Group Limited |
Dry powder medicament formulations
|
|
TWI249515B
(en)
|
2001-11-13 |
2006-02-21 |
Theravance Inc |
Aryl aniline beta2 adrenergic receptor agonists
|
|
US20030229058A1
(en)
|
2001-11-13 |
2003-12-11 |
Moran Edmund J. |
Aryl aniline beta2 adrenergic receptor agonists
|
|
JP2005523268A
(ja)
*
|
2002-02-04 |
2005-08-04 |
グラクソ グループ リミテッド |
グルココルチコイドおよびβ2−アドレナリン受容体アゴニストを含む吸入用製剤
|
|
EP1507754A1
(en)
|
2002-05-28 |
2005-02-23 |
Theravance, Inc. |
Alkoxy aryl beta-2 adrenergic receptor agonists
|
|
GB2389530B
(en)
|
2002-06-14 |
2007-01-10 |
Cipla Ltd |
Pharmaceutical compositions
|
|
AU2003298094A1
(en)
*
|
2002-10-22 |
2004-05-13 |
Glaxo Group Limited |
Medicinal arylethanolamine compounds
|
|
GB0225540D0
(en)
*
|
2002-11-01 |
2002-12-11 |
Glaxo Group Ltd |
Medicinal compounds
|
|
PE20040950A1
(es)
|
2003-02-14 |
2005-01-01 |
Theravance Inc |
DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
|
|
GB0303396D0
(en)
|
2003-02-14 |
2003-03-19 |
Glaxo Group Ltd |
Medicinal compounds
|
|
EP1622875B1
(en)
|
2003-05-08 |
2009-12-02 |
Theravance, Inc. |
Crystalline forms of an arylaniline beta-2 adrenergic receptor agonist
|
|
TW200510277A
(en)
|
2003-05-27 |
2005-03-16 |
Theravance Inc |
Crystalline form of β2-adrenergic receptor agonist
|
|
GB0316290D0
(en)
|
2003-07-11 |
2003-08-13 |
Glaxo Group Ltd |
Novel compounds
|
|
TW200526547A
(en)
*
|
2003-09-22 |
2005-08-16 |
Theravance Inc |
Amino-substituted ethylamino β2 adrenergic receptor agonists
|
|
DE102004001413A1
(de)
*
|
2004-01-09 |
2005-08-18 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
3-Hydroxymethyl-4-Hydroxy-Phenyl-Derivate zur Behandlung von chronisch obstruktiver Lungenerkrankung
|
|
TW200531692A
(en)
*
|
2004-01-12 |
2005-10-01 |
Theravance Inc |
Aryl aniline derivatives as β2 adrenergic receptor agonists
|
|
GB0401334D0
(en)
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
|
TWI341836B
(en)
|
2004-03-11 |
2011-05-11 |
Theravance Inc |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
GB0411056D0
(en)
|
2004-05-18 |
2004-06-23 |
Novartis Ag |
Organic compounds
|
|
AR049384A1
(es)
|
2004-05-24 |
2006-07-26 |
Glaxo Group Ltd |
Derivados de purina
|
|
US7402673B2
(en)
*
|
2004-06-03 |
2008-07-22 |
Theravance, Inc. |
Diamine β2 adrenergic receptor agonists
|
|
TWI307630B
(en)
|
2004-07-01 |
2009-03-21 |
Glaxo Group Ltd |
Immunoglobulins
|
|
US7317023B2
(en)
*
|
2004-07-21 |
2008-01-08 |
Theravance, Inc. |
Diaryl ether β2 adrenergic receptor agonists
|
|
GB0418045D0
(en)
|
2004-08-12 |
2004-09-15 |
Glaxo Group Ltd |
Compounds
|
|
EP1833822A2
(en)
|
2004-08-16 |
2007-09-19 |
Theravance, Inc. |
Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
|
|
EP1778626A1
(en)
|
2004-08-16 |
2007-05-02 |
Theravance, Inc. |
Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
|
|
WO2006031556A2
(en)
*
|
2004-09-10 |
2006-03-23 |
Theravance. Inc. |
Amidine substituted aryl aniline compounds
|
|
GT200500281A
(es)
|
2004-10-22 |
2006-04-24 |
Novartis Ag |
Compuestos organicos.
|
|
GB0424284D0
(en)
|
2004-11-02 |
2004-12-01 |
Novartis Ag |
Organic compounds
|
|
GB0426164D0
(en)
|
2004-11-29 |
2004-12-29 |
Novartis Ag |
Organic compounds
|
|
EP1841780B1
(en)
|
2005-01-10 |
2011-07-27 |
Glaxo Group Limited |
Androstane 17-alpha-carbonate derivatives for use in the treatment of allergic and inflammatory conditions
|
|
MY145343A
(en)
|
2005-03-25 |
2012-01-31 |
Glaxo Group Ltd |
Novel compounds
|
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
|
ES2265276B1
(es)
|
2005-05-20 |
2008-02-01 |
Laboratorios Almirall S.A. |
Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
|
|
GB0514809D0
(en)
|
2005-07-19 |
2005-08-24 |
Glaxo Group Ltd |
Compounds
|
|
RU2442771C2
(ru)
|
2005-08-08 |
2012-02-20 |
Арджента Дискавери Лтд |
Производные бицикло[2,2,1]гепт-7-иламина и их применения
|
|
GB0516313D0
(en)
|
2005-08-08 |
2005-09-14 |
Argenta Discovery Ltd |
Azole derivatives and their uses
|
|
MY144906A
(en)
|
2005-10-21 |
2011-11-30 |
Novartis Ag |
Human antibodies against il13 and therapeutic uses
|
|
TW200730498A
(en)
|
2005-12-20 |
2007-08-16 |
Glaxo Group Ltd |
Compounds
|
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
|
KR20090003349A
(ko)
|
2006-04-20 |
2009-01-09 |
글락소 그룹 리미티드 |
화합물
|
|
PE20080361A1
(es)
|
2006-04-21 |
2008-06-03 |
Novartis Ag |
Compuestos derivados de purina como activadores del receptor de adenosina a2a
|
|
GB0611587D0
(en)
|
2006-06-12 |
2006-07-19 |
Glaxo Group Ltd |
Novel compounds
|
|
AR061571A1
(es)
|
2006-06-23 |
2008-09-03 |
Smithkline Beecham Corp |
Compuesto sal del acido toluenosulfonico de 4-{[6-cloro-3-({[(2- cloro-3-fluorofenil) amino]carbonil} amino)- 2- hidroxifenil]sulfonil] -1- piperazinacarbxilato de 1.1-dimetiletilo, composicion farmaceutica que lo comprende su uso para la fabricacion de un medicamento combinacion farmaceutica con un
|
|
CA2659539A1
(en)
|
2006-08-01 |
2008-02-07 |
Glaxo Group Limited |
Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
|
|
DE602007011670D1
(de)
|
2007-01-10 |
2011-02-10 |
Irm Llc |
Verbindungen und zusammensetzungen als kanal-aktivierende proteasehemmer
|
|
US20100239551A1
(en)
|
2007-02-09 |
2010-09-23 |
Irm Llc |
Compounds and compositions as channel activating protease inhibitors
|
|
PE20081889A1
(es)
|
2007-03-23 |
2009-03-05 |
Smithkline Beecham Corp |
Indol carboxamidas como inhibidores de ikk2
|
|
US8318935B2
(en)
|
2007-05-07 |
2012-11-27 |
Novartis Ag |
Organic compounds 75074
|
|
ES2320961B1
(es)
|
2007-11-28 |
2010-03-17 |
Laboratorios Almirall, S.A. |
Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
|
|
EP2231280B1
(en)
|
2007-12-10 |
2016-08-10 |
Novartis AG |
Amiloride-like Pyrazine-carboxamides as ENaC blockers
|
|
KR20100113557A
(ko)
|
2008-01-11 |
2010-10-21 |
노파르티스 아게 |
키나제 억제제로서의 피리미딘
|
|
BRPI0912267A2
(pt)
|
2008-05-23 |
2015-10-13 |
Amira Pharmaceuticals Inc |
sal farmaceuticamente aceitável, composição farmacêutica, artigo de fabricação, métodos para tratar asma, rinite alérgica, doença, lesões gástricas e dor, métodos para prevenir broncoconstrição e rinite alérgica, uso de um sal farmaceuticamente aceitável, e, processo para a preparação de um sal farmaceuticamente aceitável.
|
|
ES2566339T3
(es)
|
2008-06-05 |
2016-04-12 |
Glaxo Group Limited |
Derivados de 4-carboxamida indazol útiles como inhibidores de PI3-quinasas
|
|
BRPI0915018A2
(pt)
|
2008-06-10 |
2015-10-27 |
Novartis Ag |
compostos orgânicos
|
|
US8236786B2
(en)
|
2008-08-07 |
2012-08-07 |
Pulmagen Therapeutics (Inflammation) Limited |
Respiratory disease treatment
|
|
EP2379507B1
(en)
|
2008-12-30 |
2013-10-16 |
Pulmagen Therapeutics (Inflammation) Limited |
Sulfonamide compounds for the treatment of respiratory disorders
|
|
WO2010094643A1
(en)
|
2009-02-17 |
2010-08-26 |
Glaxo Group Limited |
Quinoline derivatives and their uses for rhinitis and urticaria
|
|
US8524751B2
(en)
|
2009-03-09 |
2013-09-03 |
GlaxoSmithKline Intellecutual Property Development |
4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
|
|
JP2012520257A
(ja)
|
2009-03-10 |
2012-09-06 |
グラクソ グループ リミテッド |
Ikk2阻害剤としてのインドール誘導体
|
|
EP2228368A1
(en)
|
2009-03-12 |
2010-09-15 |
Almirall, S.A. |
Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
|
|
EP2408769A1
(en)
|
2009-03-17 |
2012-01-25 |
Glaxo Group Limited |
Pyrimidine derivatives used as itk inhibitors
|
|
EA201171144A1
(ru)
|
2009-03-19 |
2012-04-30 |
Мерк Шарп Энд Домэ Корп. |
ОПОСРЕДОВАННОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНА ГОМОЛОГА 1 BTB И CNC, ОСНОВНОГО ФАКТОРА ТРАНСКРИПЦИИ С ЛЕЙЦИНОВОЙ МОЛНИЕЙ 1 (Bach1) С ИСПОЛЬЗОВАНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
|
|
EP2408916A2
(en)
|
2009-03-19 |
2012-01-25 |
Merck Sharp&Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
WO2010107958A1
(en)
|
2009-03-19 |
2010-09-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
JP2012520685A
(ja)
|
2009-03-19 |
2012-09-10 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸(siNA)を用いたGATA結合タンパク質3(GATA3)遺伝子発現のRNA干渉媒介性阻害
|
|
US20120022142A1
(en)
|
2009-03-27 |
2012-01-26 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
|
JP2012521760A
(ja)
|
2009-03-27 |
2012-09-20 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸(siNA)を用いたアポトーシスシグナル調節キナーゼ1(ASK1)遺伝子発現のRNA干渉媒介性阻害
|
|
WO2010111468A2
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
|
|
KR20110138223A
(ko)
|
2009-03-27 |
2011-12-26 |
머크 샤프 앤드 돔 코포레이션 |
짧은 간섭 핵산 (siNA)을 사용한 세포간 부착 분자 1 (ICAM-1) 유전자 발현의 RNA 간섭 매개 억제
|
|
US20120022143A1
(en)
|
2009-03-27 |
2012-01-26 |
Merck Sharp & Dohme Corp |
RNA Interference Mediated Inhibition of the Thymic Stromal Lymphopoietin (TSLP) Gene Expression Using Short Interfering Nucliec Acid (siNA)
|
|
EP2421834A1
(en)
|
2009-04-24 |
2012-02-29 |
Glaxo Group Limited |
Pyrazole and triazole carboxamides as crac channel inhibitors
|
|
US20100273744A1
(en)
|
2009-04-24 |
2010-10-28 |
Paul Martin Gore |
Compounds
|
|
CN102459253B
(zh)
|
2009-04-30 |
2015-03-25 |
葛兰素集团有限公司 |
作为pi3-激酶抑制剂的*唑取代的吲唑化合物
|
|
WO2010150014A1
(en)
|
2009-06-24 |
2010-12-29 |
Pulmagen Therapeutics (Inflammation) Limited |
5r- 5 -deuterated glitazones for respiratory disease treatment
|
|
HUE026414T2
(hu)
|
2009-07-15 |
2016-05-30 |
Theravance Biopharma R&D Ip Llc |
Bifenil-vegyület kristályos szabad-bázis formája
|
|
EP2813227A1
(en)
|
2009-10-22 |
2014-12-17 |
Vertex Pharmaceuticals Incorporated |
Compositions for treatment of cystic fibrosis and other chronic diseases
|
|
GB0918924D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Azaindole derivatives
|
|
GB0918923D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Aminothiazole derivatives
|
|
GB0918922D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Aminopyridine derivatives
|
|
US20120238559A1
(en)
|
2009-12-03 |
2012-09-20 |
Glaxo Group Limited |
Novel compounds
|
|
WO2011067366A1
(en)
|
2009-12-03 |
2011-06-09 |
Glaxo Group Limited |
Indazole derivatives as pi 3 - kinase inhibitors
|
|
EP2507223A1
(en)
|
2009-12-03 |
2012-10-10 |
Glaxo Group Limited |
Benzpyrazole derivatives as inhibitors of p13 kinases
|
|
US20120272951A1
(en)
|
2009-12-16 |
2012-11-01 |
3M Innovative Properties Company |
Formulations and methods for controlling mdi particle size delivery
|
|
WO2011098746A1
(en)
|
2010-02-09 |
2011-08-18 |
Pulmagen Therapeutics (Inflammation) Limited |
Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
|
|
GB201002243D0
(en)
|
2010-02-10 |
2010-03-31 |
Argenta Therapeutics Ltd |
Respiratory disease treatment
|
|
GB201002224D0
(en)
|
2010-02-10 |
2010-03-31 |
Argenta Therapeutics Ltd |
Respiratory disease treatment
|
|
WO2011110575A1
(en)
|
2010-03-11 |
2011-09-15 |
Glaxo Group Limited |
Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
|
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
|
GB201007203D0
(en)
|
2010-04-29 |
2010-06-16 |
Glaxo Group Ltd |
Novel compounds
|
|
JP5965402B2
(ja)
|
2010-09-08 |
2016-08-03 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
N−[5−[4−(5−{[(2r,6s)−2,6−ジメチル−4−モルホリニル]メチル}−1,3−オキサゾール−2−イル)−1h−インダゾール−6−イル]−2−(メチルオキシ)−3−ピリジニル]メタンスルホンアミドの多形体および塩
|
|
UY33597A
(es)
|
2010-09-09 |
2012-04-30 |
Irm Llc |
Compuestos y composiciones como inhibidores de la trk
|
|
WO2012034095A1
(en)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
|
WO2012035055A1
(en)
|
2010-09-17 |
2012-03-22 |
Glaxo Group Limited |
Novel compounds
|
|
US8372845B2
(en)
|
2010-09-17 |
2013-02-12 |
Novartis Ag |
Pyrazine derivatives as enac blockers
|
|
EP2630126B1
(en)
|
2010-10-21 |
2015-01-07 |
Glaxo Group Limited |
Pyrazole compounds acting against allergic, immune and inflammatory conditions
|
|
EP2630127A1
(en)
|
2010-10-21 |
2013-08-28 |
Glaxo Group Limited |
Pyrazole compounds acting against allergic, inflammatory and immune disorders
|
|
GB201018124D0
(en)
|
2010-10-27 |
2010-12-08 |
Glaxo Group Ltd |
Polymorphs and salts
|
|
KR20140014184A
(ko)
|
2011-02-25 |
2014-02-05 |
아이알엠 엘엘씨 |
Trk 억제제로서의 화합물 및 조성물
|
|
US20140005188A1
(en)
|
2011-03-11 |
2014-01-02 |
Glaxo Group Limited |
Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
|
|
GB201104153D0
(en)
|
2011-03-11 |
2011-04-27 |
Glaxo Group Ltd |
Novel compounds
|
|
US8883819B2
(en)
|
2011-09-01 |
2014-11-11 |
Irm Llc |
Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
|
|
WO2013038381A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine/pyrazine amide derivatives
|
|
WO2013038373A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
|
ES2558457T3
(es)
|
2011-09-16 |
2016-02-04 |
Novartis Ag |
Compuestos heterocíclicos para el tratamiento de fibrosis quística
|
|
US9056867B2
(en)
|
2011-09-16 |
2015-06-16 |
Novartis Ag |
N-substituted heterocyclyl carboxamides
|
|
WO2013038378A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
|
EP2578570A1
(en)
|
2011-10-07 |
2013-04-10 |
Almirall, S.A. |
Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
|
|
US8809340B2
(en)
|
2012-03-19 |
2014-08-19 |
Novartis Ag |
Crystalline form
|
|
EP2641900A1
(en)
|
2012-03-20 |
2013-09-25 |
Almirall, S.A. |
Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
|
|
US9073921B2
(en)
|
2013-03-01 |
2015-07-07 |
Novartis Ag |
Salt forms of bicyclic heterocyclic derivatives
|
|
US9700558B2
(en)
|
2013-03-15 |
2017-07-11 |
Verona Pharma Plc |
Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor antagonist
|
|
WO2015055691A1
(en)
|
2013-10-17 |
2015-04-23 |
Glaxosmithkline Intellectual Property Development Limited |
Pi3k inhibitor for treatment of respiratory disease
|
|
EP3057587A1
(en)
|
2013-10-17 |
2016-08-24 |
GlaxoSmithKline Intellectual Property Development Limited |
Pi3k inhibitor for treatment of respiratory disease
|
|
CN106458980A
(zh)
|
2014-04-24 |
2017-02-22 |
诺华股份有限公司 |
作为磷脂酰肌醇3‑激酶抑制剂的氨基吡啶衍生物
|
|
KR20160141856A
(ko)
|
2014-04-24 |
2016-12-09 |
노파르티스 아게 |
포스파티딜이노시톨 3-키나제 억제제로서의 피라진 유도체
|
|
BR112016024533A8
(pt)
|
2014-04-24 |
2021-03-30 |
Novartis Ag |
derivados de amino pirazina como inibidores de fosfatidilinositol 3-cinase ou sal, seu uso, e composição e combinação farmacêuticas
|
|
TW201625247A
(zh)
|
2014-05-12 |
2016-07-16 |
葛蘭素史密斯克藍智慧財產權有限公司 |
用於治療傳染性疾病之醫藥組合物
|
|
GB201602527D0
(en)
|
2016-02-12 |
2016-03-30 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
|
JP2019524792A
(ja)
|
2016-08-08 |
2019-09-05 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
化合物
|
|
GB201706102D0
(en)
|
2017-04-18 |
2017-05-31 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
|
GB201712081D0
(en)
|
2017-07-27 |
2017-09-13 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
|
KR20220019015A
(ko)
|
2019-06-10 |
2022-02-15 |
노파르티스 아게 |
Cf, copd, 및 기관지확장증 치료를 위한 피리딘 및 피라진 유도체
|
|
UY38860A
(es)
|
2019-08-28 |
2021-02-26 |
Novartis Ag |
Derivados de 1,3–fenil heteroarilo sustituidos, composiciones para su uso en el tratamiento de enfermedades y formas cristalinas
|
|
CN110698356A
(zh)
*
|
2019-11-07 |
2020-01-17 |
南京恒远科技开发有限公司 |
N-苄基甘氨酸乙酯的制备及纯化方法
|
|
TW202140550A
(zh)
|
2020-01-29 |
2021-11-01 |
瑞士商諾華公司 |
使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法
|
|
CN114057712A
(zh)
*
|
2021-12-03 |
2022-02-18 |
广东莱佛士制药技术有限公司 |
一种合成手性苯基噁唑烷-2-酮的方法
|